FOSTER CITY, Calif.--Nycomed Amersham last week said its life science unit, Amersham Pharma-cia Biotech, was granted two favorable rulings by a California District Court in its intellectual property action against PE Biosys-tems. The lawsuit relates to use of energy transfer dyes that are used to enable high throughput DNA sequencing. Amersham, which licenses rights to US Patent No.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.